MOESM1 of A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

Additional file 1: Table S1. Schedule of enrolment, interventions and assessments.